ArticleCancer gene therapy2005
Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus.
Article in Cancer gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Glioma tumor microenvironment and immunotherapy: past, present, and future.Biomarker research · 2025Review
- Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.Journal for immunotherapy of cancer · 2021Review
- Article
- Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies.Frontiers in oncology · 2014Review
- Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.Future microbiology · 2012Review
- Retargeting of viruses to generate oncolytic agents.Advances in virology · 2012Article
- Avian paramyxovirus serotype-1: a review of disease distribution, clinical symptoms, and laboratory diagnostics.Veterinary medicine international · 2012Article
- [Anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2010Article
- The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting.Cancer immunology, immunotherapy : CII · 2010Article
- Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer.Methods in molecular biology (Clifton, N.J.) · 2009Review
- Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.Gene therapy · 2008Article
- Expression of transgenes from newcastle disease virus with a segmented genome.Journal of virology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We developed a novel strategy to target recombinant Newcastle disease virus (NDV) to tumor cells for gene therapy. Modifying the virus with a bispecific fusion protein allowed virus receptor-independent tumor cell binding and gene transfer. The targeting molecule (alpha)HN-IL-2 contains an scFv antibody cloned from a neutralizing hemagglutinin-neuraminidase (HN)-specific hybridoma linked to the human cytokine IL-2. A recombinant NDV expressing the enhanced green fluorescent protein (NDFL-EGFP) was applied to show the expression of foreign genes in virus-infected tumor cells. At 24 hours after infection with the modified virus (NDFL-EGFP/(alpha)HN-IL-2), FACS analysis and fluorescence microscopy revealed neutralization of natural infection in IL-2 receptor-negative Jurkat leukemia cells, but targeted expression of EGFP in IL-2 receptor-positive human leukemia-derived MT-2 cells. The targeted gene delivery of NDFL-EGFP/(alpha)HN-IL-2 in MT-2 cells was blocked by the target ligand human IL-2. Selective virus entry to IL-2 receptor bearing tumor cells was also observed in a mixture of Jurkat and MT-2 cell lines. These results demonstrate that a recombinant NDV carrying a foreign gene can be successfully targeted to a specific tumor through a bispecific protein, which thereby increases the selectivity of gene transfer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.